Neurocrine Biosciences (NASDAQ:NBIX) Given New $116.00 Price Target at Mizuho

Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) had its price objective hoisted by stock analysts at Mizuho from $105.00 to $116.00 in a report issued on Wednesday, Marketbeat reports. The firm presently has a “neutral” rating on the stock. Mizuho’s target price indicates a potential downside of 6.53% from the company’s previous close. Other equities research […]

Related Keywords

Canada ,Neurocrine Biosciences ,Malcolm Lloyd Smith ,Darin Lippoldt ,Neurocrine Biosciences Inc ,Red Spruce Capital ,Neurocrine Biosciences Company Profile ,Nasdaq ,Grandfield Dodd ,Cantor Fitzgerald ,Vanguard Personalized Indexing Management ,Larson Financial Group ,Barclays ,Citigroup ,Royal Bank ,Meiji Yasuda Asset Management Co Ltd ,Get Rating ,Spruce Capital ,Financial Group ,Personalized Indexing Management ,Neurocrine Biosciences Daily ,Nasdaq Nbix ,Nbix ,Medical ,64125c10 ,Boost Price Target ,Mizuho ,